Mobius Therapeutics

Focus: Mobius Therapeutics is a specialty pharmaceutical company focused on ophthalmic perioperative pharmaceuticals, based in St. Louis with a diversified pipeline spanning neurology and ophthalmology.

Neurology Ophthalmology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Mobius Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Mobius Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

JointRep®

Chondral Defect

N/A

Clinical Trials (1)

NCT04840147A Comparison of JointRep® and Microfracture in Repair of Cartilage Lesions on the Femoral Condyle or Trochlea,

N/A

Help build intelligence for Mobius Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused specialty in ophthalmic perioperative space addresses underserved market with high unmet needs
Diversified pipeline across neurology, ophthalmology, and rare diseases shows broad therapeutic reach
Early-stage programs (Phase 1-2) offer opportunity to shape novel drug development from preclinical through clinical

Watch Out For

Zero current job openings and minimal public visibility suggests limited near-term hiring or momentum
Early pipeline stage (no Phase 3 programs) and lack of marketed products means long runway to revenue and uncertain exit trajectory
Absence of financial, funding, and employee data raises questions about company stability and resources

Generated by Claude from Mobius Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

44Ch Bionic Eye Device

Retinitis Pigmentosa

N/A

Clinical Trials (1)

NCT03406416Study of a Suprachoroidal Retinal Prosthesis

N/A

BromAc

COVID-19 Pneumonia

Phase 1

Clinical Trials (1)

NCT05220605Nebulised BromAc in Healthy Volunteers

Phase 1